e-learning
resources
Berlin 2001
Tuesday 25.09.2001
Factors contributing to upper and lower airway responses
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of the effects of zafirlucast and montelucast therapy on the airway hiperreactivity in asthmatic patients
I. Akbas, T. Cengiz, B. Musellim, T. Demir, B. Mutlu (Istanbul, Turkey)
Source:
Annual Congress 2001 - Factors contributing to upper and lower airway responses
Session:
Factors contributing to upper and lower airway responses
Session type:
Thematic Poster Session
Number:
2893
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Akbas, T. Cengiz, B. Musellim, T. Demir, B. Mutlu (Istanbul, Turkey). Comparison of the effects of zafirlucast and montelucast therapy on the airway hiperreactivity in asthmatic patients. Eur Respir J 2001; 16: Suppl. 31, 2893
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients
Source: Annual Congress 2010 - COPD: management
Year: 2010
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast
versus
salmeterol
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Effect of add-on montelukast to inhaled corticosteroids on excessive airway narrowing in adult asthmatics
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Combined treatment with fluticasone plus salmeterol protects against allergen-induced asthmatic responses better than each drug alone
Source: Eur Respir J 2001; 18: Suppl. 33, 349s
Year: 2001
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Inhaled budesonide/formoterol combination therapy significantly attenuates allergen-induced increases in airway myfibroblasts
Source: Eur Respir J 2007; 30: Suppl. 51, 137s
Year: 2007
The effect of fluticasone
vs
fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma
Source: Eur Respir J 2001; 17: 374-379
Year: 2001
Efficacy of symbicort administration in patients with bronchial asthma
Source: Annual Congress 2009 - Treatment of airways disease
Year: 2009
Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD
Source: International Congress 2018 – Advances in exercise physiopathology
Year: 2018
Safety of formoterol reliever therapy compared with terbutaline in asthmatic children taking anti-inflammatory therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 431s
Year: 2002
Effects of a single inhaled budesonide/formoterol dose on glucocorticoid receptor activity in sputum of COPD patients
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
Effect of fluticasone and formoterol combination therapy on airway remodeling
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011
The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 341s
Year: 2004
Efficacy of long-term formoterol therapy
vs
as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001
Evening administration of tiotropium during combination therapy reduces night-symptoms in COPD patients
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Response to salbutamol in patients with mild asthma treated with nadolol
Source: Eur Respir J 2010; 36: 963-965
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept